These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6443750)

  • 21. [The use of L-deprenyl in Parkinson's disease].
    Zhonghua Yi Xue Za Zhi; 1983 Mar; 63(3):147-9. PubMed ID: 6409375
    [No Abstract]   [Full Text] [Related]  

  • 22. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
    Sivertsen B; Dupont E; Mikkelsen B; Mogensen P; Rasmussen C; Boesen F; Heinonen E
    Acta Neurol Scand Suppl; 1989; 126():147-52. PubMed ID: 2515720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of Parkinson's syndrome using a new preparation from the series of tricyclic psychotropic drugs].
    Deze J; Völler GW
    Med Welt; 1975 Aug; 26(33-34):1457-62. PubMed ID: 1100988
    [No Abstract]   [Full Text] [Related]  

  • 24. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 25. Selegiline in Parkinson's disease.
    Teräväinen H
    Acta Neurol Scand; 1990 Apr; 81(4):333-6. PubMed ID: 2113756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
    Birkmayer W; Knoll J; Riederer P; Youdim MB
    Mod Probl Pharmacopsychiatry; 1983; 19():170-6. PubMed ID: 6408405
    [No Abstract]   [Full Text] [Related]  

  • 27. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long term treatment with L-deprenyl.
    Birkmayer W
    J Neural Transm; 1978; 43(3-4):239-44. PubMed ID: 745016
    [No Abstract]   [Full Text] [Related]  

  • 30. [Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Nervenarzt; 1977 Apr; 48(4):205-10. PubMed ID: 404579
    [No Abstract]   [Full Text] [Related]  

  • 31. L-deprenyl treatment of on-off phenomena in Parkinson's disease.
    Rinne UK; Siirtola T; Sonninen V
    J Neural Transm; 1978; 43(3-4):253-62. PubMed ID: 745018
    [No Abstract]   [Full Text] [Related]  

  • 32. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term course in Parkinson's syndrome and cerebral polypathy (Parkinson plus).
    Fischer PA
    Adv Neurol; 1987; 45():235-8. PubMed ID: 3825695
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Slowing the progression of Parkinson syndrome by early administration of deprenyl].
    Baas H; Fischer PA
    Nervenarzt; 1990 Feb; 61(2):127-9. PubMed ID: 2108395
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A new drug for Parkinson's disease: selegiline (Eldeprine). Copenhagen, January 26-27, 1989].
    D'Anglejan-Chatillon J
    Rev Prat; 1989 Oct; 39(22):1978. PubMed ID: 2510243
    [No Abstract]   [Full Text] [Related]  

  • 38. [Experience with a l-dopa retard preparation in the peroral long-term therapy of the Parkinsonian syndrome].
    Binder H; Gerstenbrand F; Grünberger J; Gründig E; Schubert H
    Nervenarzt; 1976 Nov; 47(11):656-60. PubMed ID: 826840
    [No Abstract]   [Full Text] [Related]  

  • 39. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent observations on the clinical pharmacology of (-)deprenyl.
    Stern GM; Lees AJ; Sandler M
    J Neural Transm; 1978; 43(3-4):245-51. PubMed ID: 745017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.